FDA Looks to Raise Survival Bar for Cancer Drug Approvals in New Draft Guidance
The FDA recommends that companies use overall survival as a primary endpoint for clinical trials where feasible. The new guidance follows the surprising return of CBER Head Vinay Prasad, who has previously argued for prioritizing OS.
FDA Looks to Raise Survival Bar for Cancer Drug Approvals in New Draft Guidance Read More »
